



MaxCyte, Inc.
("MaxCyte" or the "Company")

Declaration of Audit Remuneration

Gaithersburg, Maryland, USA – XX October 2018: MaxCyte (LSE: MXCT, MXCR), the global cell-based medicines and life sciences company, in order to assist investors in considering the resolutions proposed ahead of its 2018 AGM, notes that the remuneration of the Company's auditors, Aronson LLC, for the financial year ended 2017 for audit-related services amounted to approximately \$90,000 plus approximately \$10,000 for non-audit related services.

The Annual General Meeting of Stockholders is planned to be held at 11 a.m. BST on 31 October 2018 at 21 Firstfield Road, Suite 202, Gaithersburg, MD 20878, USA.

About MaxCyte

MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, with all of the top ten global biopharmaceutical companies, has more than 55 partnered programme licences in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com

###

For further information, please contact:

MaxCyte Inc.

+1 301 944 1660

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer

Nominated Adviser and Broker

Panmure Gordon

+44 (0)20 7886 2500

Emma Earl

Freddy Crossley

Ryan McCarthy

Corporate Broking

James Stearns

Financial PR Adviser

Consilium Strategic Communications

+44 (0)203 709 5700

Mary-Jane Elliott

maxcyte@consilium-comms.com

Chris Welsh

Sukaina Virji